Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin - powder and solvent for solution for injection - 1.2 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - somatropin - powder and solvent for solution for injection - 10 milligram(s)/millilitre - somatropin and somatropin agonists; somatropin

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 6 mg (equivalent: somatropin, qty 18 iu) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; glycerol; hydrochloric acid; metacresol - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 12 mg (equivalent: somatropin, qty 36 iu) - injection, solution - excipient ingredients: hydrochloric acid; metacresol; sodium hydroxide; glycerol; water for injections - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 24 mg (equivalent: somatropin, qty 72 iu) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; glycerol; sodium hydroxide; metacresol - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)

United States - English - NLM (National Library of Medicine)

dna labs, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), long-(arg3)insulin-like growth factor-i (unii: m9l22y19h9) (long-(arg3)insulin-like growth factor-i - unii:m9l22y19h9), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), saw palmetto (unii: j7wwh9m8qs) (saw palmetto - unii:j7wwh9m8qs), platinum (unii: 49dfr088my) (platinum - unii:49dfr088my), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e32821g6i), bos tau - muscle weakness, reduced energy and vitality.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 16 iu - diluent, not applicable - excipient ingredients: metacresol; water for injections - short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 20 march 2001: short stature due to decreased or failed secretion of pituitary hormone. growth distrubances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 26 november 2001: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanograms/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituit

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5.3 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - somatropin, recombinant human growth hormone - powder and solvent for solution for injection - 8 milligram(s) - somatropin and somatropin agonists; somatropin

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin -